Janux Therapeutics
JANX
198 hedge funds and large institutions have $933M invested in Janux Therapeutics in 2026 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 83 increasing their positions, 45 reducing their positions, and 30 closing their positions.
84% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 45
37% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 30
20% more call options, than puts
Call options by funds: $4.44M | Put options by funds: $3.71M
13% more capital invested
Capital invested by funds: $828M → $933M (+$106M)
4% more funds holding
Funds holding: 190 → 198 (+8)
1.73% more ownership
Funds ownership: 97.95% → 99.68% (+1.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$33.3M |
| 2 |
Two Sigma Investments
New York
|
+$15.8M |
| 3 |
D.E. Shaw & Co
New York
|
+$14.5M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$12.3M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$12.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$16.5M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$13.9M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$12.7M |
| 4 |
ICM
Irenic Capital Management
New York
|
-$10.6M |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
-$6.95M |
JANX Hedge Fund Activity: Q2 2026 in Review
198 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Janux Therapeutics (JANX) for Q2 2026, worth a combined $933M — up 13% from $828M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new JANX positions and 30 closed out — a net gain of 11 holders — while 83 added to existing stakes and 45 trimmed.
The largest buyer was Federated Hermes, adding an estimated $33.3M. The largest seller was Deep Track Capital, exiting entirely with an estimated $16.5M sold.
- 198 institutional investors held Janux Therapeutics (JANX) as of Q2 2026, up from 190 in Q1 2026.
- Funds reported $933M of Janux Therapeutics stock for Q2 2026, up 13% quarter-over-quarter.
- 41 funds opened new Janux Therapeutics positions in Q2 2026 and 30 closed out, a net change of +11 holders.
- The largest Janux Therapeutics buyer in Q2 2026 was Federated Hermes, an estimated $33.3M added.
- The largest Janux Therapeutics seller in Q2 2026 was Deep Track Capital, an estimated $16.5M sold.
Based on aggregated 13F filings for Q2 2026.